Nobis Aleksander, Zalewski Daniel, Waszkiewicz Napoleon
Department of Psychiatry, Medical University of Bialystok, pl. Brodowicza 1, 16-070 Choroszcz, Poland.
J Clin Med. 2020 Nov 24;9(12):3793. doi: 10.3390/jcm9123793.
Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers-C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles.
重度抑郁症(MDD)是全球致残的主要原因,造成了高昂的医疗和社会经济负担。人们对抑郁症的生物学基础越来越感兴趣,这反映在生物标志物水平的改变上。其中,MDD患者体内炎症增强,炎症标志物如C反应蛋白、白细胞介素-6、肿瘤坏死因子-α和可溶性白细胞介素-2受体的浓度升高。氧化应激和亚硝化应激也在MDD的病理生理学中发挥作用。值得注意的是,脂质过氧化标志物水平升高是MDD的特征。MDD患者还存在应激轴失调以及皮质醇水平升高的情况。此外,在MDD患者中还发现生长因子发生改变,脑源性神经营养因子显著减少,成纤维细胞生长因子-2和胰岛素样生长因子-1浓度增加。最后,犬尿氨酸代谢产物、谷氨酸增加和总胆固醇降低也有望成为MDD可靠的生物标志物。对MDD发病机制的认识不足、该疾病的显著异质性、常见的共病以及生物标志物的低特异性阻碍了MDD生物标志物领域的研究。构建生物标志物组合并利用新技术对其进行评估可能有潜力克服上述障碍。